Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs - Reuters
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs Reuters
The biotechnology sector is experiencing rapid advancements in gene-editing technologies, making such licensing deals increasingly common as pharmaceutical companies seek innovative therapeutic approaches.
This deal signifies a major pharmaceutical company's commitment to gene-editing for chronic diseases, potentially accelerating the development and commercialization of new treatments for kidney disease.
Lilly now has access to a specific gene-editing platform to target kidney disease, potentially shifting future drug development strategies in this therapeutic area.
- · Lilly
- · Ascidian
- · Gene-editing technology sector
- · Patients with kidney disease
- · Traditional drug development methods for kidney disease
Lilly initiates pre-clinical or clinical trials for gene-edited kidney disease therapies.
Increased investment and licensing activity in gene-editing platforms targeting a wider range of chronic conditions.
Gene-editing becomes a standard modality in pharmaceutical pipelines for previously untreatable or poorly managed diseases, leading to significant healthcare cost shifts.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Reuters — Technology (Google News)